Table 4. Summary of base-case, sensitivity and subgroup analysis results.
| Indication | Treatment and comparator strategies | Base-case (21–25% cirrhotic*) ICERs | DSA ranges | PSA | Subgroup (100% cirrhotic) ICERs | Subgroup (100% non-cirrhotic) ICERs |
|---|---|---|---|---|---|---|
| GT1 TN IE | SOF + PegIFN2a + RBV for 12 wks vs. PegIFN2a/2b + RBV for 48 wks | 19.474 | 6,339–31,668 | 100% of ICERs<100,000 | 1,565 | 36,501 |
| SOF + PegIFN2a + RBV for 12 wks vs. TEL + PegIFN2a + RBV for 24/48 wks | 10,337 | SOF dominant-44,639 | 98.2% of ICERs<100,000 | SOF dominant | 28,608 | |
| SOF + PegIFN2a + RBV for 12 wks vs. BOC + PegIFN2b + RBV for 28/48 wks | 13,276 | SOF dominant-35,975 | 100% of ICERs<100,000 | 963 | 26,579 | |
| GT1 TN II | SOF + RBV for 24 wks vs. NT | 86,648 | 42,713–148,297 | 50.8% of ICERs<100,000 | 75,799 | 95,741 |
| GT2 TN IE | SOF + RBV for 12 wks vs. PegIFN2a/2b + RBV for 24 wks | 76,526 | 40,468–138,263 | 58.7% of ICERs<100,000 | 35,302 | 115,138 |
| GT2 TN II | SOF + RBV for 12 wks vs. NT | 10,471 | 1,080–19,273 | 100% of ICERs<100,000 | SOF dominant | 17,808 |
| GT3 TN IE | SOF + RBV for 24 wks vs. PegIFN2a/2b + RBV for 24 wks | 91,570 | 47,672–130,036 | 48.9% of ICERs<100,000 | 28,384 | 189,063 |
| SOF + PegIFN2a + RBV for 12 wks vs. PegIFN2a/2b + RBV for 24 wks | 38,512 | 17,109–57,694 | 97.4% of ICERs<100,000 | 8,491 | 74,341 | |
| GT3 TN II | SOF + RBV for 24 wks vs. NT | 34,826 | 14,649–53,365 | 99.5% of ICERs<100,000 | 17,275 | 46,900 |
| GT3 TE IE | SOF + RBV for 24 wks vs. PegIFN2a/2b + RBV for 48 wks | 74,805 | 38,237–112,762 | 65.8% of ICERs<100,000 | 90,653 | 76,064 |
| SOF + PegIFN2a + RBV for 12 wks vs. PegIFN2a/2b + RBV for 48 wks | 16,235 | 4,314–26,946 | 99.7% of ICERs<100,000 | 4,382 | 24,957 | |
| GT3 TE II | SOF + RBV for 24 wks vs. NT | 45,935 | 20,783–68,920 | 96.6% of ICERs<100,000 | 36,189 | 52,720 |
| GT4 TN | SOF + PegIFN2a + RBV for 12 wks vs. PegIFN2a/2b + RBV for 48 wks | 36,108 | 17,738–87,678 | 83.9% of ICERs<100,000 | 89,131 | 33,054 |
BOC, boceprevir; DSA, deterministic sensitivity analysis; GT, genotype; ICER, incremental cost-effectiveness ratio; IE, interferon eligible; II, interferon ineligible; PegIFN, pegylated interferon; PSA, probabilistic sensitivity analysis; RBV, ribavirin; SOF, sofosbuvir; TE, treatment-experienced; TEL, telaprevir; TN, treatment-naïve; wks, weeks
* percentage of cirrhotic patients depends on genotype: 24% in genotype 1, 21% in genotype 2, 25% in genotype 3 and 22% in genotype 4